| Literature DB >> 35025975 |
Ayman Elbehiry1,2, Musaad Aldubaib3, Osamah Al Rugaie4, Eman Marzouk1, Marwan Abaalkhail5, Ihab Moussa6,7, Mohamed H El-Husseiny8, Adil Abalkhail1, Mohammed Rawway9,10.
Abstract
Brucellae are intracellular sneaky bacteria and they can elude the host's defensive mechanisms, resulting in therapeutic failure. Therefore, the goal of this investigation was to rapid identification of Brucella species collected from animals and humans in Saudi Arabia, as well as to evaluate their resistance to antibiotics. On selective media, 364 animal samples as well as 70 human blood samples were cultured. Serological and biochemical approaches were initially used to identify a total of 25 probable cultured isolates. The proteomics of Brucella species were identified using the MALDI Biotyper (MBT) system, which was subsequently verified using real-time polymerase chain reaction (real-time PCR) and microfluidic electrophoresis assays. Both Brucella melitensis (B. melitensis) and Brucella abortus (B. abortus) were tested for antimicrobial susceptibility using Kirby Bauer method and the E-test. In total, 25 samples were positive for Brucella and included 11 B. melitensis and 14 B. abortus isolates. Twenty-two out of 25 (88%) and 24/25 (96%) of Brucella strains were recognized through the Vitek 2 Compact system. While MBT was magnificently identified 100% of the strains at the species level with a score value more than or equal to 2.00. Trimethoprim-sulfamethoxazole, rifampin, ampicillin-sulbactam, and ampicillin resistance in B. melitensis was 36.36%, 31.82%, 27.27%, and 22.70%, respectively. Rifampin, trimethoprim-sulfamethoxazole, ampicillin, and ampicillin-sulbactam resistance was found in 35.71%, 32.14%, 32.14%, and 28.57% of B. abortus isolates, correspondingly. MBT confirmed by microfluidic electrophoresis is a successful approach for identifying Brucella species at the species level. The resistance of B. melitensis and B. abortus to various antibiotics should be investigated in future studies.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35025975 PMCID: PMC8757992 DOI: 10.1371/journal.pone.0262551
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Oligonucleotide sequences used in the current study.
| Species | Target sequence | Forward (F) primer/reverse (R) primer (5′→3′) | Base pair (bp) size | Reference | |
|---|---|---|---|---|---|
|
| F |
| 112 | [ | |
| R |
| ||||
|
| F |
| 222 | ||
| R |
| ||||
Zone diameter and MIC breakpoints for Haemophilus spp. as an alternative for Brucella species [52].
| Antibiotic used | Disc content in μg | Zone diameter breakpoints in mm | MIC breakpoints in μg/ml | ||||
|---|---|---|---|---|---|---|---|
| S | I | R | S | I | R | ||
| Ampicillin | 10 | ≥22 | 19–21 | ≤18 | ≤1 | 2 | ≥4 |
| Ampicillin-sulbactam | 10/10 | ≥20 | - | ≤19 | ≤ 2/1 | – | ≥ 4/2 |
| Cefuroxime | 30 | ≥20 | 17–19 | ≤16 | ≤4 | 8 | ≥16 |
| Tetracycline | 30 | ≥29 | 26–28 | ≤25 | ≤2 | 4 | ≥8 |
| Doxycycline | 30 | ≥48 | 32–47 | ≤31 | ≤1 | - | - |
| Ciprofloxacin | 5 | ≥ 21 | - | ≤20 | ≤1 | - | - |
| levofloxacin | 5 | ≥ 17 | 18–19 | ≤20 | ≤2 | - | - |
| Trimethoprim- sulfamethoxazole | 1.25/23.75 | ≥16 | 11–15 | ≤10 | ≤ 0.5/9.5 | 1/19–2/38 | ≥ 4/76 |
| Chloramphenicol | 30 | ≥29 | 26–28 | ≤25 | ≤2 | 4 | ≥8 |
| Rifampin | 5 | ≥20 | 17–19 | ≤16 | ≤1 | 2 | ≥4 |
| Gentamycin | 10 | ≥45 | 23–44 | ≤22 | ≤4 | - | - |
| Streptomycin | 10 | ≥36 | 20–35 | ≤19 | ≤8 | - | - |
Different types of samples used in the study and Brucella isolates.
| Species | Type of sample | Total | ||||||
|---|---|---|---|---|---|---|---|---|
| Milk | Blood | Vaginal swab | ||||||
| Sample cultured | Isolates | Sample cultured | Isolates | Sample cultured | Isolates | Total samples cultured | Total isolates | |
|
| 80 | 5 | 80 | 3 | 80 | 6 | 240 | 14 |
|
| 44 | 1 | 40 | 2 | 40 | 2 | 124 | 5 |
|
| 0 | 0 | 70 | 6 | 0 | 0 | 70 | 6 |
Fig 1Protein patterns of Brucella melitensis strain.
Fig 2Protein patterns of field Brucella abortus strain.
Logarithmic score values for B. melitensis and B. abortus strains isolated from human blood samples and milk and vaginal swab samples of animals by MBT.
| Brucella spp. | Total number | Score value of identification | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 2.3–3 | 2–2.29 | 1.7–1.99 | 0–1.69 | ||||||
| No. | % | No. | % | No. | % | No. | % | ||
| 11 | 3 | 27.27 | 8 | 72.73 | 0 | 0.00 | 0 | 0.00 | |
| 14 | 5 | 35.71 | 8 | 57.14 | 1 | 3.57 | 0 | 0.00 | |
Fig 3Principal component analysis developed a 3D loading image that shows many spectra for 11 Brucella melitensis and 14 Brucella abortus strains.
The force value of the peaks was represented by each dot. The peaks were adjusted in accordance with the loading value, which corresponded to loading 1, loading 2, and loading 3 modes.
MBT and molecular identification, as well as culturing of B. melitensis and B. abortus isolated from human animal species in Saudi Arabia.
| ID of sample | Species | Sample’s origin | Sample’s type | Selective culture media | MBT identification | Real time PCR | |
|---|---|---|---|---|---|---|---|
| Species | Score value | ||||||
| CM-1 | Cattle | Bukiryah | Milk | Positive | 2.12 | ||
| CM-2 | Cattle | Bukiryah | Milk | Positive | 2.31 | ||
| CM-3 | Cattle | Unayzah | Milk | Positive | 2.16 | ||
| CM-4 | Cattle | Unayzah | Milk | Positive | 2.43 | ||
| CM-5 | Cattle | Ar Rass | Milk | Positive | 2.08 | ||
| CB-6 | Cattle | Ar Rass | Blood | Positive | 2.29 | ||
| CB-7 | Cattle | Ar Rass | Blood | Positive | 2.30 | ||
| CB-8 | Cattle | Ar Rass | Blood | Positive | 2.22 | ||
| CV-9 | Cattle | Bukiryah | Vagina | Positive | 2.41 | ||
| CV-10 | Cattle | Buraydah | Vagina | Positive | 2.14 | ||
| CV-11 | Cattle | Unayzah | Vagina | Positive/Negative | 1.98 | ||
| CV-12 | Cattle | Buraydah | Vagina | Positive | 2.18 | ||
| CV-13 | Cattle | Unayzah | Vagina | Positive | 2.39 | ||
| CV-14 | Cattle | Unayzah | Vagina | Positive | 2.21 | ||
| GM-15 | Goat | Unayzah | Milk | Positive | 2.24 | ||
| GM-16 | Goat | Ar Rass | Blood | Positive | 2.32 | ||
| GM-17 | Goat | Ar Rass | Blood | Positive | 2.00 | ||
| GM-18 | Goat | Buraydah | Vagina | Positive | 2.23 | ||
| GM-19 | Goat | Buraydah | Vagina | Positive | 2.15 | ||
| HB-20 | Human | Buraydah | Blood | Positive | 2.41 | ||
| HB-21 | Human | Buraydah | Blood | Positive | 2.07 | ||
| HB-22 | Human | Buraydah | Blood | Positive | 2.36 | ||
| HB-23 | Human | Buraydah | Blood | Positive | 2.18 | ||
| HB-24 | Human | Riyadh | Blood | Positive | 2.10 | ||
| HB-25 | Human | Riyadh | Blood | Positive | 2.20 | ||
The MIC values of antimicrobial agents against 25 Brucella strains (11 B. melitensis and 14 B. abortus).
| Antimicrobial agent | Conc. in μg/ml | Range of MIC | MIC50 in μg/ml | MIC90 in μg/ml | |||
|---|---|---|---|---|---|---|---|
| AMP | 0.016–256 | 0.25–6 | 0.19–4 | 0.38 | 1.5 | 4 | 2 |
| AMS | 0.016–256 | 0.125–6 | 0.094–6 | 1 | 0.75 | 1.5 | 3 |
| CXM | 0.016–256 | 0.75–8 | 0.5–6 | 1.5 | 1.5 | 2 | 0.75 |
| TE | 0.016–256 | 0.064–8 | 0.094–8 | 0.125 | 0.19 | 0.25 | 0.75 |
| DXT | 0.016–256 | 0.032–4 | 0.047–4 | 0.094 | 0.125 | 0.19 | 0.25 |
| CIP | 0.002–32 | 0.023–0.19 | 0.023–0.25 | 0.047 | 0.19 | 0.125 | 0.094 |
| LEV | 0.002–32 | 0.032–1.5 | 0.094–1 | 0.75 | 0.50 | 1 | 0.75 |
| SXT | 0.002–32 | 0.012–4 | 0.016–0.25 | 0.047 | 0.19 | 0.125 | 0.38 |
| C | 0.016–256 | 0.032–0.75 | 0.023–0.5 | 0.064 | 0.094 | 0.25 | 0.19 |
| RIF | 0.016–256 | 0.125–6 | 0.094–12 | 0.19 | 4 | 4 | 6 |
| CN | 0.064–1024 | 0.38–6 | 0.50–6 | 0.75 | 0.75 | 1 | 0.50 |
| S | 0.016–256 | 0.023–8 | 0.032–8 | 0.125 | 0.19 | 0.38 | 0.75 |
AMP = ampicillin; AMS = ampicillin-sulbactam; CXM = cefuroxime; TE = tetracycline; DXT = doxycycline; CIP = ciprofloxacin; LEV = levofloxacin, SXT = trimethoprim- sulfamethoxazole; C = chloramphenicol; RIF = rifampin; CN = gentamycin; S = streptomycin
Kirby Bauer method for determining antibiotic sensitivity of B. melitensis and B. abortus isolates.
| Antimicrobial agent | Conc. in μg/ml | Range in mm | Degree of susceptibility | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B. melitensis (n = 11) | B. abortus (n = 14) | ||||||||||||||
| B. melitensis | B. abortus | S | I | R | S | I | R | ||||||||
| No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | ||||
| AMP | 10 | 13–35 | 16–34 | 17 | 77.30 | 0 | 0 | 5 | 22.7 | 19 | 67.86 | 0 | 0 | 9 | 32.14 |
| AMS | 10/10 | 14–30 | 12–33 | 16 | 72.73 | 0 | 0 | 6 | 27.27 | 20 | 71.43 | 0 | 0 | 8 | 28.57 |
| CXM | 30 | 24–37 | 22–41 | 22 | 100.0 | 0 | 0 | 0 | 0.00 | 28 | 100.0 | 0 | 0 | 0 | 0.00 |
| TE | 30 | 25–40 | 25–38 | 20 | 90.91 | 0 | 0 | 2 | 9.10 | 25 | 89.29 | 0 | 0 | 3 | 10.71 |
| DXT | 30 | 26–52 | 27–51 | 20 | 90.10 | 0 | 0 | 2 | 9.10 | 26 | 92.86 | 0 | 0 | 2 | 7.14 |
| CIP | 5 | 22–37 | 24–40 | 22 | 100.0 | 0 | 0 | 0 | 0.00 | 28 | 100.0 | 0 | 0 | 0 | 0.00 |
| LEV | 5 | 18–29 | 17–32 | 22 | 100.0 | 0 | 0 | 0 | 0.00 | 28 | 100.0 | 0 | 0 | 0 | 0.00 |
| SXT | 1.25/23.75 | 7–23 | 6–24 | 14 | 63.64 | 0 | 0 | 8 | 36.36 | 17 | 60.71 | 2 | 7.14 | 9 | 32.14 |
| C | 30 | 25–42 | 26–38 | 19 | 86.36 | 0 | 0 | 3 | 13.66 | 26 | 92.86 | 0 | 0 | 2 | 7.14 |
| RIF | 5 | 13–28 | 12–30 | 11 | 50.00 | 4 | 18.18 | 7 | 31.82 | 15 | 53.57 | 3 | 10.71 | 10 | 35.71 |
| CN | 10 | 23–48 | 22–51 | 22 | 100.0 | 0 | 0 | 0 | 0.00 | 22 | 78.57 | 5 | 17.86 | 1 | 3.57 |
| S | 10 | 17–45 | 19–43 | 19 | 86.36 | 1 | 4.55 | 2 | 9.10 | 25 | 89.29 | 1 | 3.57 | 2 | 7.14 |
AMP = ampicillin; AMS = ampicillin-sulbactam; CXM = cefuroxime; TE = tetracycline; DXT = doxycycline; CIP = ciprofloxacin; LEV = levofloxacin, SXT = trimethoprim- sulfamethoxazole; C = chloramphenicol; RIF = rifampin; CN = gentamycin; S = streptomycin
Multidrug resistance profile of 25 Brucella species.
| No. of antibiotics | Antibiotic profiles | Resistant strains | No. of antibiotic classes | Resistance category | |
|---|---|---|---|---|---|
| No. | % | ||||
| 5 | AMP, TE, DXT, SXT, RIF | 2 | 8% | 4 | Multidrug resistant |
| 5 | AMS, TE, SXT, RIF, S | 2 | 8% | 5 | Multidrug resistant |
| 5 | AMS, TE, DXT, SXT, S | 1 | 4% | 4 | Multidrug resistant |
| 4 | AMP, AMS, DXT, RIF | 1 | 4% | 3 | Multidrug resistant |
| 4 | AMP, AMS, TE, SXT | 1 | 4% | 3 | Multidrug resistant |
| 3 | AMS, SXT, RIF | 3 | 12% | 3 | Multidrug resistant |
| 3 | C, RIF, CN | 1 | 4% | 3 | Multidrug resistant |
| 3 | AMP, AMS, SXT | 1 | 4% | 2 | Drug resistant |
| 3 | AMP, AMS, RIF | 2 | 8% | 2 | Drug resistant |
| 3 | SXT, RIF, S | 1 | 4% | 3 | Multidrug resistant |
| 3 | AMP, AMS, C | 1 | 4% | 2 | Drug resistant |
| 3 | SXT, C, RIF | 1 | 4% | 2 | Drug resistant |
| 3 | AMP, AMS, RIF | 1 | 4% | 2 | Drug resistant |
| 2 | AMS, SXT | 1 | 4% | 2 | Drug resistant |
| 2 | SXT, RIF | 2 | 8% | 2 | Drug resistant |
| 2 | AMS, RIF | 1 | 4% | 2 | Drug resistant |
| 2 | C, RIF | 2 | 8% | 2 | Drug resistant |
| 1 | RIF | 1 | 4% | 1 | Drug resistant |